ArticleAnnals of surgery open : perspectives of surgical history, education, and clinical approaches2025
A Randomized Open-Label, Noninferiority, Phase 3, Multicenter, Controlled Trial to Compare Laparoscopic Surgery With Open Surgery for Symptomatic, Noncurable Stage IV Colorectal Cancer (JCOG1107).
Article in Annals of surgery open : perspectives of surgical history, education, and clinical approaches, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To confirm noninferiority of laparoscopic (LAP) to open surgery (OP) for progression-free survival (PFS) of patients with non-curable stage IV colorectal cancer (CRC). Background: Benefits of LAP versus OP are suggested, but long-term survival following LAP for symptomatic, noncurable CRC remains unclear. Methods: In this open-label, multicenter, randomized controlled trial, only accredited surgeons from 42 Japanese institutions participated. Eligibility criteria included pathologically proven adenocarcinoma or adenosquamous carcinoma; primary tumor anywhere in the colon causing bowel stenosis and/or bleeding; and at least 1 to 3 noncurable factors. Patients received mFOLFOX6+bevacizumab or CapeOX+bevacizumab postoperatively and were randomly assigned 1:1 to the OP or LAP group. The primary endpoint was PFS, with noninferiority margin for the hazard ratio (HR) set at 1.38. Results: Between January 2013 and January 2021, 195 patients were randomized (OP, n = 95, LAP, n = 100). Ninety-two patients received OP and 98 LAP, with 82 OP and 86 LAP patients receiving postoperative chemotherapy. Median PFS was 9.7 months (95% CI = 8.7-11.3) for OP and 10.4 months (9.1-12.4) for LAP. Noninferiority of LAP was confirmed [HR = 1.02; 91.4% CI = 0.79-1.32 (<1.38), Conclusions: LAP appears to be an acceptable standard treatment for symptomatic, noncurable stage IV CRC. Trial registration: UMIN-CTR, number UMIN000009715.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.